HC Wainwright assumed coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN) in a report published on Wednesday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $1.25 price objective on the stock.

Shares of DFFN stock opened at $0.64 on Wednesday. Diffusion Pharmaceuticals has a fifty-two week low of $0.59 and a fifty-two week high of $5.06.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/diffusion-pharmaceuticals-dffn-now-covered-by-analysts-at-hc-wainwright/1956551.html.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.